Sapphire Therapeutics Overview
- Year Founded
-
2000
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
- Investors
-
1
Sapphire Therapeutics General Information
Description
Operator of biopharmaceutical company. The company develops and commercialize compounds that are ready for clinical or preclinical testing in oncologic and metabolic diseases.
Contact Information
Website
www.sapphirethera.comCorporate Office
- 1031 United States Highway 22
- Suite 303
- Bridgewater, NJ 08807
- United States
Corporate Office
- 1031 United States Highway 22
- Suite 303
- Bridgewater, NJ 08807
- United States
Sapphire Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Merger/Acquisition | 28-Jan-2009 | Completed | Clinical Trials - Phase 2 | |||
| 3. Later Stage VC | 14-Jun-2006 | Completed | Clinical Trials - Phase 2 | |||
| 2. Early Stage VC (Series B) | 12-Sep-2005 | $40M | $52M | Completed | Clinical Trials - Phase 2 | |
| 1. Early Stage VC (Series A) | 01-Apr-2001 | $12M | $12M | Completed | Product Development |
Sapphire Therapeutics Patents
Sapphire Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20070191283-A1 | Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues | Inactive | 12-Aug-2004 | ||
| US-20160046667-A1 | Crystal forms of anamorelin | Active | 29-Jun-2004 | ||
| US-9975921-B2 | Crystal forms of anamorelin | Inactive | 29-Jun-2004 | ||
| US-20070004638-A1 | Form c dihydrates; useful as they act directly on the pituitary gland cells to release growth hormone; storage stability | Active | 29-Jun-2004 | ||
| US-7825138-B2 | Form c dihydrates; useful as they act directly on the pituitary gland cells to release growth hormone; storage stability | Active | 29-Jun-2004 | C07K5/0202 |
Sapphire Therapeutics Former Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| BCM Ventures | Venture Capital | Minority | ||
| BankInvest Biotech Ventures | Venture Capital | Minority | ||
| Baylor College of Medicine | University | Minority | ||
| Boston Millennia Partners | Venture Capital | Minority | ||
| Burrill & Co | Merchant Banking Firm | Minority |
Sapphire Therapeutics FAQs
-
When was Sapphire Therapeutics founded?
Sapphire Therapeutics was founded in 2000.
-
Where is Sapphire Therapeutics headquartered?
Sapphire Therapeutics is headquartered in Bridgewater, NJ.
-
What industry is Sapphire Therapeutics in?
Sapphire Therapeutics’s primary industry is Biotechnology.
-
Is Sapphire Therapeutics a private or public company?
Sapphire Therapeutics is a Private company.
-
What is Sapphire Therapeutics’s current revenue?
The current revenue for Sapphire Therapeutics is .
-
How much funding has Sapphire Therapeutics raised over time?
Sapphire Therapeutics has raised $59.5M.
-
Who are Sapphire Therapeutics’s investors?
BCM Ventures, BankInvest Biotech Ventures, Baylor College of Medicine, Boston Millennia Partners, and Burrill & Co are 5 of 11 investors who have invested in Sapphire Therapeutics.
-
When was Sapphire Therapeutics acquired?
Sapphire Therapeutics was acquired on 28-Jan-2009.
-
Who acquired Sapphire Therapeutics?
Sapphire Therapeutics was acquired by Helsinn Healthcare.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process